SCHEMBL16639870

SCHEMBL16639870

CC(C)C1(N)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
ATM Q13315 2/20 0.43
HPGD P15428 1/20 0.42
EPHX2 P34913 1/20 0.41
HTT P42858 2/20 0.41
RECQL P46063 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX1 P07099 1/20 0.40
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15657911 0.89 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL15447125 0.83 USP2 (0.51) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL15797471 0.83 USP2 (0.43) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL18383750 0.83 TSHR (0.43) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL28889805 0.83 USP2 (0.45) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL10290907 0.82 USP2 (0.55) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL16000449 0.81 USP2 (0.50) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL12349928 0.81 USP2 (0.50) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL182080 0.81 USP2 (0.53) USP2SMN1; SMN2TSHRALOX15ATM
SCHEMBL3648747 0.81 USP2 (0.46) USP2SMN1; SMN2TSHRALOX15ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3725787-B1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS INC (US) 2023-11-29 EP disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 US disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 US disclosed
US-20210179559-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2021-06-17 US disclosed
US-10968180-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2021-04-06 US disclosed
EP-3055299-B1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS INC (US) 2021-01-06 EP disclosed
EP-3292113-B1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2020-07-08 EP disclosed
US-10358421-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2019-07-23 US disclosed
US-9790180-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2017-10-17 US disclosed
US-20160279128-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS, INC. 2016-09-29 US disclosed
US-20160279128-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS, INC. 2016-09-29 US disclosed
US-20160168093-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2016-06-16 US disclosed
US-20160168093-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2016-06-16 US disclosed
US-9278963-B2 Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2016-03-08 US disclosed
US-9278963-B2 Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2016-03-08 US disclosed
WO-2015054474-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS, INC. (US) 2015-04-16 WO disclosed
US-20150105384-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS, INC. (US) 2015-04-16 US disclosed
US-20150105384-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS ACETYLON PHARMACEUTICALS, INC. (US) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168093-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885
US-20210179559-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885
US-20160279128-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC2 USP2 3241/4885SMN1; SMN2 190/4885TSHR 3969/4885
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885
US-10968180-B2 Piperidine derivatives as HDAC1/2 inhibitors HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885
US-20150105384-A1 PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC2 USP2 3241/4885SMN1; SMN2 190/4885TSHR 3969/4885
US-10358421-B2 Piperidine derivatives as HDAC1/2 inhibitors HDAC1, HDAC2, HDAC10 USP2 723/4885SMN1; SMN2 1134/4885TSHR 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.